FTRE Stock Forecast & Price Target

Fortrea Holdings is viewed positively because management raised its 2026 revenue guide to $2.665B-$2.69B and adjusted EBITDA to $210M-$218M, signaling improved execution after earlier operational difficulties tied to the spinoff. The company also has clear margin catalysts from operating leverage, favorable trial mix, cost savings, and direct-fee conversion, with direct-fee margins up more than 200 bps year to date despite limited revenue growth. In addition, the Worldwide acquisition should expand CPS capabilities and utilization, while improving biotech demand, rising large-pharma activity, and stronger backlog conversion support a credible path to higher revenue and profitability.

Fortrea Holdings is facing a negative fundamental setup because the CRO industry is exposed to weaker outsourcing demand, reduced biopharma R&D spend, and contract losses if macroeconomic softness or regulatory pressure constrains sponsor budgets. The company also does not expect a net bookings benefit, and the one-time backlog adjustment suggests existing contract visibility is being reset to reflect inactive studies and scope changes, which underscores execution uncertainty rather than strengthening demand. In addition, fierce pricing competition, wage inflation, and the risk that large pharma favors larger CROs could pressure revenue growth, margins, and investor confidence.